A Multivariable Prediction Model for Pneumocystis jirovecii Pneumonia in Hematology Patients with Acute Respiratory Failure

2018 ◽  
Vol 198 (12) ◽  
pp. 1519-1526 ◽  
Author(s):  
Elie Azoulay ◽  
Antoine Roux ◽  
François Vincent ◽  
Achille Kouatchet ◽  
Laurent Argaud ◽  
...  
Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4876-4876
Author(s):  
Mukta Kumar ◽  
William Keough

Abstract Abstract 4876 Pneumocystis jirovecii is an opportunistic pathogen responsible for severe pneumonia in immunocompromised patients. Management of this pneumonia remains a major challenge for all physicians caring for immunosuppressed patients. The prognosis of Pneumocystis jirovecii pneumonia (PCP) with acute respiratory failure is traditionally known to be poor. We report a case of PCP in a child with recently diagnosed childhood Precursor B cell Acute Lymphoblastic Leukemia (ALL). Course was complicated with acute respiratory failure showing hypoxemia, respiratory failure requiring intubation and reduced compliance resembling ARDS. Our Patient, 8 weeks into chemotherapy for newly diagnosed ALL, presented with high grade fevers and poor activity. Patient was admitted 3 weeks prior for Bacillus cereus bacteremia. Additionally the patient had been on broad spectrum antibiotics on 2 occasions for febrile neutropenia episodes within the past 2 weeks. Patient had minimal respiratory symptoms at this presentation and recovered from pancytopenia at the time of this presentation. CT scans and chest x-ray (Figures 1 and 2) showed diffuse marked ground glass opacities with dependent consolidation in the lungs. On day 3 of admission, bronchoalveolar lavage (BAL) was preformed and empiric trimethoprim-sulfamethoxazole was initiated in addition to broad spectrum antibacterial, antifungal and antiviral medications. Within 24 hours, patient rapidly deteriorated with significant respiratory distress and hypoxemia requiring intubation. Clinical and radiologic findings were suggestive of ARDS. Patient required significant ventilatory support, fluid restriction, diuretics, and steroids. PCR testing of BAL fluid was reported as positive for Pneumocystis jirovecii. By hospital day 6 the patient was still requiring a fair amount of respiratory support. Corticosteroids had been added but concern amongst some members of the team surrounded possible lack of efficacy of trimethoprim-sulfamethoxazole. Review of published case reports suggested that addition of caspofungin provided salvage therapy in cases where trimethoprim-sulfamethoxazole was believed to be suboptimal. Caspofungin was added to this patient's treatment. However, liver trans-aminases experienced a 2–3 fold increase within 72 hours after initiating caspofungin. Caspofungin was withdrawn but the patient's condition gradually improved and was extubated 7 days later. Also of note, there have been wide spread regional and national shortages of intravenous trimethoprim-sulfamethoxazole preparations. We were forced to convert to oral therapy several days after extubation. The patient continued to improve and had no signs of complications or increased morbidity from this conversion; however, this was a continued concern during his treatment. A Pub Med review of the literature reveals very little failure of trimethoprim-sulfamethoxazole prophylaxis in the non-HIV immunocompromised population. Further, studies in Denmark, Italy, and the UK reveal that trimethoprim-sulfamethoxazole prophylaxis in children with ALL also decreases the number of febrile and bacteremic incidents. Trimethoprim-sulfamethoxazole also has advantages over other prophylactic choices against Pneumocystis jirovecii with fewer side effects such as methemoglobinemia induced by dapsone for example. Other studies from the UK, US, and Denmark stress that the early diagnosis and treatment with appropriate antimicrobials and possibly corticosteroids has a better outcome in this frequently fatal complication of immunosupressed patients. This case stresses the need for continued patient education regarding adherence to prophylactic regimens, early diagnosis and suspicion of opportunistic organisms such as Pneumocystis jirovecii, and prompt diagnosis and treatment of the same.Figure 1.Ground Glass Opacities on CT ChestFigure 1. Ground Glass Opacities on CT ChestFigure 2.Chest x-ray infiltratesFigure 2. Chest x-ray infiltrates Disclosures: No relevant conflicts of interest to declare.


2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Ji Soo Choi ◽  
Se Hyun Kwak ◽  
Min Chul Kim ◽  
Chang Hwan Seol ◽  
Sung Ryeol Kim ◽  
...  

Abstract Background Pneumocystis jirovecii pneumonia (PCP) with acute respiratory failure can result in development of pneumothorax during treatment. This study aimed to identify the incidence and related factors of pneumothorax in patients with PCP and acute respiratory failure and to analyze their prognosis. Methods We retrospectively reviewed the occurrence of pneumothorax, including clinical characteristics and results of other examinations, in 119 non-human immunodeficiency virus patients with PCP and respiratory failure requiring mechanical ventilator treatment in a medical intensive care unit (ICU) at a tertiary-care center between July 2016 and April 2019. Results During follow up duration, twenty-two patients (18.5%) developed pneumothorax during ventilator treatment, with 45 (37.8%) eventually requiring a tracheostomy due to weaning failure. Cytomegalovirus co-infection (odds ratio 13.9; p = 0.013) was related with occurrence of pneumothorax in multivariate analysis. And development of pneumothorax was not associated with need for tracheostomy and mortality. Furthermore, analysis of survivor after 28 days in ICU, patients without pneumothorax were significantly more successful in weaning from mechanical ventilator than the patients with pneumothorax (44% vs. 13.3%, p = 0.037). PCP patients without pneumothorax showed successful home discharges compared to those who without pneumothorax (p = 0.010). Conclusions The development of pneumothorax increased in PCP patient with cytomegalovirus co-infection, pneumothorax might have difficulty in and prolonged weaning from mechanical ventilators, which clinicians should be aware of when planning treatment for such patients.


2021 ◽  
Author(s):  
Ji Soo Choi ◽  
Se Hyun Kwak ◽  
Min Chul Kim ◽  
Chang Hwan Seol ◽  
Sung Ryeol Kim ◽  
...  

Abstract Background: Pneumocystis jirovecii pneumonia (PCP) with acute respiratory failure can result in development of pneumothorax during treatment. This study aimed to identify the incidence and related factors of pneumothorax in patients with PCP and acute respiratory failure and to analyze their prognosis.Methods: We retrospectively reviewed the occurrence of pneumothorax, including clinical characteristics and results of other examinations, in 119 non-human immunodeficiency virus patients with PCP and respiratory failure requiring mechanical ventilator treatment ina medical intensive care unit (ICU) at a tertiary-care center between July 2016 and April 2019.Results: The 28-day survival rate was 62.2% (N=74). Twenty-two patients (18.5%) developed pneumothorax during ventilator treatment, with 45 (37.8%) eventually requiringa tracheostomy due to weaning failure. Cytomegalovirus co-infection (odds ratio 13.9; p=0.013) was related with occurrence of pneumothorax. Of 74 patients with 28-day survival data, 15 (20.3%) developed pneumothorax. In those patients, five survived (p=0.048) and only two were successfully weaned from mechanical ventilation (p=0.037).Conclusions: Patients with PCP and acute respiratory failure who developed pneumothorax did not have increased 28-day mortality, however pneumothorax increased in patient with cytomegalovirus co-infection, pneumothoraxmight have difficulty in and prolonged weaning from mechanical ventilators, which clinicians should be aware of when planning treatment for such patients.


2021 ◽  
Author(s):  
Ji Soo Choi ◽  
Se Hyun Kwak ◽  
Min Chul Kim ◽  
Chang Hwan Seol ◽  
Sung Ryeol Kim ◽  
...  

Abstract Background: Pneumocystis jirovecii pneumonia (PCP) with acute respiratory failure can result in development of pneumothorax during treatment. This study aimed to identify the incidence and related factors of pneumothorax in patients with PCP and acute respiratory failure and to analyze their prognosis.Methods: We retrospectively reviewed the occurrence of pneumothorax, including clinical characteristics and results of other examinations, in 119 non-human immunodeficiency virus patients with PCP and respiratory failure requiring mechanical ventilator treatment in a medical intensive care unit (ICU) at a tertiary-care center between July 2016 and April 2019.Results: The 28-day survival rate was 62.2% (N=74). Twenty-two patients (18.5%) developed pneumothorax during ventilator treatment, with 45 (37.8%) eventually requiring a tracheostomy due to weaning failure. Cytomegalovirus co-infection (odds ratio 13.9; p=0.013) was related with occurrence of pneumothorax. Of 74 patients with 28-day survival data, 15 (20.3%) developed pneumothorax. In those patients, five survived (p=0.048) and only two were successfully weaned from mechanical ventilation (p=0.037).Conclusions: Patients with PCP and acute respiratory failure who developed pneumothorax did not have increased 28-day mortality, however pneumothorax increased in patient with cytomegalovirus co-infection, pneumothorax might have difficulty in and prolonged weaning from mechanical ventilators, which clinicians should be aware of when planning treatment for such patients.


Author(s):  
Norihiko Goto ◽  
Kenta Futamura ◽  
Manabu Okada ◽  
Takayuki Yamamoto ◽  
Makoto Tsujita ◽  
...  

The outbreak of Pneumocystis jirovecii pneumonia (PJP) among kidney transplant recipients is emerging worldwide. It is important to control nosocomial PJP infection. A delay in diagnosis and treatment increases the number of reservoir patients and the number of cases of respiratory failure and death. Owing to the large number of kidney transplant recipients compared to other types of organ transplantation, there are greater opportunities for them to share the same time and space. Although the use of trimethoprim-sulfamethoxazole (TMP-SMX) as first choice in PJP prophylaxis is valuable for PJP that develops from infections by trophic forms, it cannot prevent or clear colonization, in which cysts are dominant. Colonization of P. jirovecii is cleared by macrophages. While recent immunosuppressive therapies have decreased the rate of rejection, over-suppressed macrophages caused by the higher levels of immunosuppression may decrease the eradication rate of colonization. Once a PJP cluster enters these populations, which are gathered in one place and uniformly undergoing immunosuppressive therapy for kidney transplantation, an outbreak can occur easily. Quick actions for PJP patients, other recipients, and medical staff of transplant centers are required. In future, lifelong prophylaxis may be required even in kidney transplant recipients.


Sign in / Sign up

Export Citation Format

Share Document